A Study of the Zanubrutinib Given in Combination With Bendamustine and Rituximab in (Elderly or TP53 Alterations or Chemotherapy Intolerance) Patients With Newly Diagnosed Mantle Cell Lymphoma

Trial Details

NCT ID

NCT06136351

Phase

PHASE2

Sponsor

Ruijin Hospital

Status

RECRUITING

Cancer Type

Non-Hodgkin Lymphoma Lymphoma

Interventions

• Zanubrutinib
• Rituximab
• Bendamustin

Locations (sample)

• Shanghai, Shanghai Municipality, China|31.22222,121.45806

Key Eligibility Criteria

• Histopathologically confirmed mantle cell lymphoma according to the 5th edition of the World Health Organization (WHO)
• FISH with del(17p)/TP53 mutation or ≥65 years; or\<65 years but chemotherapy intolerance;
• Life expectancy of \> 3 months (in the opinion of the investigator);
• Creatinine Clearance Rate (CCR) ≥ 50 mL/min or estimated Glomerular Filtration ●Rate (eGFR) ≥ 60 mL/(min·1.73 m\^2);

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.